{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:46:25Z","timestamp":1793339185290,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jcf.2024.12.010","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T23:04:23Z","timestamp":1736636663000},"page":"574-580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Effect of elexacaftor-tezacaftor-ivacaftor on liver transient elastography, fibrosis indices and blood tests in children with cystic fibrosis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1106-4424","authenticated-orcid":false,"given":"Vito","family":"Terlizzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3642-8928","authenticated-orcid":false,"given":"Cristina","family":"Fevola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Cecchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0464-6402","authenticated-orcid":false,"given":"Alberto","family":"Terminiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Curci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Bartolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7480-3613","authenticated-orcid":false,"given":"Chiara","family":"Rubino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3970-5000","authenticated-orcid":false,"given":"Mariangela","family":"Stinco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0123-5808","authenticated-orcid":false,"given":"Simona","family":"Carrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bonomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Taccetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5352-7760","authenticated-orcid":false,"given":"Zachary M.","family":"Sellers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Indolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2024.12.010_bib0001","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic Fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2024.12.010_bib0002","article-title":"Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians","author":"Terlizzi","year":"2024","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"key":"10.1016\/j.jcf.2024.12.010_bib0003","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(23)01609-4","article-title":"CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis","volume":"402","author":"Taylor-Cousar","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2024.12.010_bib0004","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2024.12.010_bib0005","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2024.12.010_bib0006","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","article-title":"Efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis heterozygous for F508del and a minimal function mutation: a phase 3b, randomized, placebo-controlled study","volume":"206","author":"Mall","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.12.010_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2024.114176","article-title":"Reported adverse events in a multicenter cohort of patients ages 6-18 years with cystic fibrosis and at least one F508del Allele receiving elexacaftor\/tezacaftor\/ivacaftor","author":"Terlizzi","year":"2024","journal-title":"J Pediatr"},{"key":"10.1016\/j.jcf.2024.12.010_bib0008","article-title":"Impact of CFTR Modulator Therapies on Liver Function in Cystic Fibrosis Patients: A Systematic Review of Hepatic Biomarkers","author":"Moiceanu","year":"2024","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.jcf.2024.12.010_bib0009","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/hep.30148","article-title":"Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients","volume":"69","author":"Bo\u00eblle","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jcf.2024.12.010_bib0010","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jhep.2021.09.042","article-title":"Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies","volume":"76","author":"Dana","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcf.2024.12.010_bib0011","article-title":"Cystic fibrosis liver disease in the new era of cystic fibrosis transmembrane conductance receptor (CFTR) modulators","author":"Eldredge","year":"2023","journal-title":"Paediatr Respir Rev"},{"issue":"Suppl 2","key":"10.1016\/j.jcf.2024.12.010_bib0012","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S1569-1993(11)60006-4","article-title":"Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease","volume":"10","author":"Debray","year":"2011","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.12.010_bib0013","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/hep.1840360613","article-title":"Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome","volume":"36","author":"Colombo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jcf.2024.12.010_bib0014","article-title":"Impact of highly effective modulator therapy on gastrointestinal symptoms and features in people with cystic fibrosis","author":"Cecchetti","year":"2024","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.jcf.2024.12.010_bib0015","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1097\/HEP.0000000000000646","article-title":"Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations","volume":"79","author":"Sellers","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jcf.2024.12.010_bib0016","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/MPG.0000000000003944","article-title":"Towards a standardized classification of the hepatobiliary manifestations in cystic fibrosis (CFHBI): a joint ESPGHAN\/NASPGHAN Position Paper","volume":"78","author":"Bodewes","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jcf.2024.12.010_bib0017","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/hep.24014","article-title":"Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy","volume":"53","author":"Lewindon","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jcf.2024.12.010_bib0018","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/MPG.0b013e31812e56ff","article-title":"Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy","volume":"45","author":"de L\u00e9dinghen","year":"2007","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jcf.2024.12.010_bib0019","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/jcag\/gwy029","article-title":"Transient elastography in the evaluation of cystic fibrosis-associated liver disease: systematic review and meta-analysis","volume":"2","author":"Lam","year":"2019","journal-title":"J Can Assoc Gastroenterol"},{"key":"10.1016\/j.jcf.2024.12.010_bib0020","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/MPG.0000000000002413","article-title":"Liver ultrasound patterns in children with cystic fibrosis correlate with noninvasive tests of liver disease","volume":"69","author":"Ling","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jcf.2024.12.010_bib0021","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/j.cgh.2019.03.015","article-title":"Accuracy of Transient Elastography Data Combined With APRI in Detection and Staging of Liver Disease in Pediatric Patients With Cystic Fibrosis","volume":"17","author":"Lewindon","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jcf.2024.12.010_bib0022","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/MPG.0000000000002412","article-title":"New Algorithm for the Integration of Ultrasound Into Cystic Fibrosis Liver Disease Screening","volume":"69","author":"Sellers","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jcf.2024.12.010_bib0023","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00247-021-05015-w","article-title":"Clinical use of shear-wave elastography for detecting liver fibrosis in children and adolescents with cystic fibrosis","volume":"51","author":"Levitte","year":"2021","journal-title":"Pediatr Radiol"},{"key":"10.1016\/j.jcf.2024.12.010_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.01.005","article-title":"Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues","author":"Burgel","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.12.010_bib0025","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations","volume":"180","author":"Flume","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.12.010_bib0026","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1164\/rccm.202301-0021OC","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in children aged \u2a7e6 years with cystic fibrosis and at least one F508del allele: a phase 3, open-label clinical trial","volume":"208","author":"Wainwright","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.12.010_bib0027","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.ultrasmedbio.2003.07.001","article-title":"Transient elastography: a new noninvasive method for assessment of hepatic fibrosis","volume":"29","author":"Sandrin","year":"2003","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.jcf.2024.12.010_bib0028","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ultrasmedbio.2010.07.005","article-title":"Controlled attenuation parameter (CAP): a novel VCTETM guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes","volume":"36","author":"Sasso","year":"2010","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.jcf.2024.12.010_bib0029","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jcf.2018.11.004","article-title":"Controlled attenuation parameter: a measure of hepatic steatosis in patients with cystic fibrosis","volume":"18","author":"Bader","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.12.010_bib0030","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/hep.30148","article-title":"French CF modifier gene study investigators. Cystic fibrosis liver disease: outcomes and risk factors in a large cohort of french patients","volume":"69","author":"Bo\u00eblle","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jcf.2024.12.010_bib0031","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.cgh.2016.03.041","article-title":"Features of severe liver disease with portal hypertension in patients with cystic fibrosis","volume":"14","author":"Stonebraker","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jcf.2024.12.010_bib0032","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.jhep.2023.02.006","article-title":"Effects of CFTR modulator therapies on liver stiffness and bile flow: A single-centre experience","volume":"79","author":"Calvo","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jcf.2024.12.010_bib0033","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jcf.2023.09.006","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor on liver fibrosis markers in adults with cystic fibrosis","volume":"23","author":"Tewkesbury","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.12.010_bib0034","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/liv.15544","article-title":"Increase of liver stiffness and altered bile acid metabolism after triple CFTR modulator initiation in children and young adults with cystic fibrosis","volume":"43","author":"Schnell","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.jcf.2024.12.010_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1157459","article-title":"Weight increase in people with cystic fibrosis on CFTR modulator therapy is mainly due to increase in fat mass","volume":"14","author":"Mouzaki","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2024.12.010_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.03.011","article-title":"Elexacaftor\/tezacaftor\/ivacaftor use in pediatric cystic fibrosis patients with advanced liver disease","author":"Protich","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2024.12.010_bib0037","doi-asserted-by":"crossref","first-page":"e0010","DOI":"10.1097\/HC9.0000000000000010","article-title":"Effects of CFTR modulators on serum biomarkers of liver fibrosis in children with cystic fibrosis","volume":"7","author":"Levitte","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jcf.2024.12.010_bib0038","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jcf.2023.01.007","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on liver tests at a large single adult cystic fibrosis centre","volume":"22","author":"Tewkesbury","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.12.010_bib0039","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1180282","article-title":"Multimodal analysis of granulocytes, monocytes, and platelets in patients with cystic fibrosis before and after Elexacaftor-Tezacaftor-Ivacaftor treatment","volume":"14","author":"Schmidt","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcf.2024.12.010_bib0040","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/kaftrio-epar-public-assessment-report_en.pdf."},{"key":"10.1016\/j.jcf.2024.12.010_bib0041","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1002\/ppul.26673","article-title":"Prevalence of adverse events in cystic fibrosis patients treated with elexacaftor\/tezacaftor\/ivacaftor: Experience of the regional referral center in Tuscany, Italy","volume":"58","author":"Manciulli","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2024.12.010_bib0042","article-title":"Ursodeoxycholic acid for cystic fibrosis-related liver disease","author":"Cheng","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jcf.2024.12.010_bib0043","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jcf.2021.03.014","article-title":"Ursodeoxycholic acid and liver disease associated with cystic fibrosis: A multicenter cohort study","volume":"21","author":"Colombo","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.12.010_bib0044","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1327958","article-title":"One year of treatment with elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation causes a significant increase in liver biochemical indexes","volume":"10","author":"Castaldo","year":"2024","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.jcf.2024.12.010_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.01.001","article-title":"Drug-induced liver injury associated with elexacaftor\/tezacaftor\/ivacaftor: A pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)","author":"Shi","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.12.010_bib0046","doi-asserted-by":"crossref","first-page":"17422","DOI":"10.1038\/s41598-024-68511-7","article-title":"Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del\/CFTR variant genotype after elexacaftor\/tezacaftor\/ivacaftor treatment","volume":"14","author":"Castaldo","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2024.12.010_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.04.006","article-title":"Safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with Cystic Fibrosis following liver transplantation: A systematic review","author":"Testa","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.12.010_bib0048","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40265-023-01969-3","article-title":"Aetiology of significant liver test abnormalities in a single-centre cohort of people with cystic fibrosis exposed to elexacaftor\/tezacaftor\/ivacaftor, utilizing the updated RUCAM","volume":"83","author":"Tewkesbury","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.jcf.2024.12.010_bib0049","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcf.2016.08.002","article-title":"Prevalence of elevated liver enzymes in children with cystic fibrosis diagnosed by newborn screen","volume":"16","author":"Woodruff","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.12.010_bib0050","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.cct.2012.11.005","article-title":"Incidence and clinical significance of elevated liver function tests in cystic fibrosis clinical trials","volume":"34","author":"Mayer-Hamblett","year":"2013","journal-title":"Contemp Clin Trials"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324018617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324018617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T16:28:57Z","timestamp":1748968137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324018617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1569199324018617"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.12.010","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of elexacaftor-tezacaftor-ivacaftor on liver transient elastography, fibrosis indices and blood tests in children with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}